Zymeworks (ZYME) Q3 2026 earnings review
Zymeworks wins its $250 million milestone, but debt jumps higher
Zymeworks, a biotechnology company that pairs drug discovery with royalty streams, booked a landmark regulatory payout while taking on heavy debt to buy a commercial lung drug. Total revenue reached $256 million after U.S. regulators approved its stomach cancer medicine Ziihera and triggered a $250 million partner payment. Chief executive Kenneth Galbraith also closed the purchase of Theravance Biopharma, licensed an early cancer drug to Roche, and raised the full-year outlook, which by our math leaves $81 million of fourth-quarter revenue.
| Revenue excluding milestones and Theravance | $5.0M +90% from a year ago by our math |
|---|---|
| Total revenue (includes $250M milestone) | $256.5M $27.6M a year ago |
| Long-term liabilities | $756.7M $269.4M last quarter |
| Full-year revenue outlook | Raised $59M middle of the range: $344M |
⚖️ Verdict: 🟢 Bullish
The story got better because the U.S. approval of Ziihera cleared the company's biggest binary risk, and the Roche deal brings in $55 million upfront while shifting trial costs off the books. One caution: the debt-funded transformation is straining the balance sheet, as cash dropped to $100 million before the October milestone arrived, long-term liabilities climbed to $757 million, and management cancelled its earnings call.
The question now is whether recurring cash from Ziihera royalties and the acquired YUPELRI inhaler can comfortably outpace interest and principal payments on $600 million of debt. Either the new commercial streams turn the business into a self-funding cash generator, or debt service and higher overhead eat up the gains. Fourth-quarter royalty revenue and net interest expense will tell.
🐂 Bull Case
FDA Approval Unlocked $250 Million and Lifted Royalties
Ziihera is a cancer antibody discovered by Zymeworks and sold by partners Jazz Pharmaceuticals and BeOne Medicines. On August 25, U.S. regulators approved the drug as an initial treatment for stomach and esophageal cancer (GEA), triggering a $250 million milestone payment that Jazz paid in October. Updated trial data in October showed the drug regimen cut the risk of death by 35%, better than the 28% seen in an earlier readout.
The approval resolved the biotechnology group's biggest single-event risk and moved its main asset into a larger patient group. Royalty revenue from partner sales rose 28% from last quarter to $2.3 million, even with less than five weeks of U.S. launch sales in the new indication. Up to $190 million in further regulatory milestones remain available if Europe, Japan and China approve the drug.
What to watch: fourth-quarter royalty revenue from Jazz and BeOne. That figure will give the first full-quarter reading on U.S. stomach cancer demand after Zymeworks diverts 30% of its royalties to service its loan.
Roche Deal Funds ZW209 and Raises the Outlook
Zymeworks needs outside partners to pay for expensive clinical trials so it can keep its own research spending down. On October 23, the drug developer signed an "exclusive global collaboration and license agreement with Roche for the development of ZW209", an experimental cancer therapy that cleared U.S. regulatory review to enter human testing this year.
Roche will pay $55 million upfront once antitrust review clears, plus $40 million when the second part of the initial trial starts, and will cover all trial costs. That upfront payment drove the $59 million increase at the middle of Zymeworks' full-year revenue outlook, proving the lab can still turn early science into immediate cash while shifting trial bills to a major pharmaceutical partner.
What to watch: clearance of the U.S. antitrust waiting period for the Roche deal in the fourth quarter. Any delay into 2027 would push the $55 million payment out of this year's results.
Theravance Deal Closed and Added Commercial Revenue
Chief executive Kenneth Galbraith wants "to build a durable financial foundation through partnered and commercial assets" rather than relying only on lumpy research milestones. On September 23, Zymeworks closed its purchase of Theravance Biopharma, "adding a recurring commercial cash-flow stream through YUPELRI", an inhaled lung medicine sold in the United States by partner Viatris.
Seven days of ownership added $1.5 million to third-quarter revenue, while hospital doses of YUPELRI grew at a double-digit pace from a year ago. Zymeworks plans to cut $13 million to $15 million in yearly overhead costs after the deal, and the combined business implies about $25.5 million of fourth-quarter revenue by our math after stripping out the Roche upfront payment.
What to watch: whether sales of Trelegy Ellipta, another inhaler tied to the Theravance purchase, hit the targets required to trigger up to $100 million in milestone payments due in early 2027.
🐻 Bear Case
Cash Dropped and Debt Climbed Before the Milestone Arrived
Galbraith said the company is entering its next phase with a stronger business after accessing $600 million in debt this year to buy Theravance and repurchase shares. That borrowing has reshaped the balance sheet: Zymeworks pledged 30% of Ziihera royalties for a $250 million Royalty Pharma loan and added a $350 million note backed by YUPELRI profits, while spending $140.4 million on buybacks over nine months.
- Cash and marketable securities: $100.5 million at September 30, down from $322.5 million in June
- Long-term liabilities: $756.7 million, up from $269.4 million in June and $35.7 million at year-end
- Net other expense: $4.4 million in Q3, swinging from $3.8 million of net income a year ago on loan interest
- Selling and administrative expenses: $42.7 million, up 202% from a year ago on deal fees, severance and stock awards
Collecting the $250 million Jazz milestone in October rebuilt the cash balance after quarter-end, because that payment sat in accounts receivable on September 30. Even so, the royalty and profit streams that Galbraith calls durable must first service $600 million of debt carrying an average cost near 10%.
What to watch: fourth-quarter net interest expense and the debt repayment schedule in the annual filing. Those figures will show how much YUPELRI and Ziihera cash stays with shareholders after debt service.
Zymeworks Cancelled Its Call During a Major Overhaul
In the first paragraph of its release, Zymeworks said it "elected not to host a third quarter earnings conference call" after already dropping its cash-runway forecast last quarter. At the same time, the biotechnology group switched its headline profit measure to earnings before interest, taxes, depreciation and one-offs (adjusted EBITDA), dropping the multi-year operating expense table it published in earlier releases.
By our math, third-quarter operating expenses excluding stock compensation, deal fees and severance reached $42.8 million, up from $35.4 million in the second quarter and well above the $29.2 million quarterly pace implied by management's earlier standalone cost target. Stepping back from live questions during an acquisition and a $600 million debt build leaves investors unable to separate standalone cost creep from seven days of Theravance expenses.
What to watch: the quarterly filing's footnotes on the Theravance purchase and debt terms. That filing will show the exact cash price paid and the standalone cost run-rate.
Risks this quarter didn't answer
Three standing concerns about pipeline partnering and outside partners received clinical updates in the release, but no commercial resolution.
- Unpartnered ovarian cancer drug (ZW191): Phase 1 data showed a 64.5% response rate that "supports continued clinical development in partnership or through a strategic collaboration", but no partner has signed yet; the February 11, 2027 R&D Day is the next checkpoint.
- Remaining $190 million of Ziihera milestones: still waiting on regulatory approvals in Europe, Japan and China; partner notices over the next two quarters will decide the timing.
- Partner trial control: Johnson & Johnson reported a 73% response rate for prostate cancer drug pasritamig, and Jazz launched Ziihera in stomach cancer, but Zymeworks still gives no underlying patient counts or launch revenue targets.
💲 Other KPIs
Accounts receivable — money owed to the drug developer by partners — rose to $413.9 million from $4.6 million at the end of 2025. The jump came mostly from the $250 million Ziihera approval milestone earned in August, which Jazz paid in cash after the quarter closed in October, plus receivables added from the Theravance purchase.
Research spending crept up 1.5% from a year ago and rose from $27.4 million in the second quarter. Lower trial spending after stopping the ZW171 program last year and finishing early lab work on newer candidates was offset by extra staff costs absorbed when the Theravance deal closed in late September.
The average basic share count fell 5.5% from 75.8 million a year ago after the biotechnology group bought back 5.7 million shares in the first nine months of 2026. Because the third quarter swung to a profit, diluted share count rose 0.6% from a year ago to 76.3 million as employee stock awards entered the calculation.
🔮 Guidance
Raised. The middle of the full-year outlook moved up by $59 million, or 225% growth over 2025. By our math, that leaves $80.5 million for the fourth quarter, down from the milestone-driven $256.5 million in the third quarter. The raise rests on the $55 million Roche upfront payment clearing antitrust review before year-end, leaving about $25.5 million from YUPELRI and royalties.
Raised. Management lifted the middle of its full-year profit target by $62 million after signing the Roche license deal. With $153.0 million already booked in the first nine months, the plan leaves about $30.0 million for the fourth quarter by our math. Comparing the revenue and profit plans implies about $50.6 million of fourth-quarter cash operating costs after consolidating Theravance.
❓ Key Questions
How much YUPELRI cash remains after OMERS loan payments?
Zymeworks borrowed $350 million backed by U.S. YUPELRI profits, but the release does not state the repayment schedule. Investors need the net cash left over after debt service to value the Theravance deal.
Is the $300 million three-year cost cap still active?
Earlier releases promised $300 million of total operating expenses from 2026 through 2028, excluding stock awards and deal costs. This release dropped that table in favor of adjusted EBITDA and ran $42.8 million of clean costs in the third quarter alone.
Why did management cancel the third-quarter conference call?
During the same quarter it closed the Theravance buyout, added $487 million in long-term liabilities, and signed the Roche deal, Zymeworks chose not to take analyst questions. That leaves purchase accounting and standalone expense trends unexplained until the filing arrives.
When will Zymeworks sign a partner for ZW191?
Updated Phase 1 data at the October medical congress showed a 64.5% response rate in ovarian cancer, and the release noted the drug is ready for a partnership. Moving into larger trials without a partner would lift research spending.